Similar to the clinical trial performed by Mittendorf et al. (2014), 1000 μg of E75 peptide in 250 μg of GM-CSF was monthly given to 376 breast cancer patients (lymph node-positive, HER2/neu by Immunohistochemistry 1/2 +) for 6 months, with placebo replacing E75 given to another 382 patients as the control. Here, ERBB2 is linked to breast carcinoma.